

PubMed

**Format:** Abstract**Full text links**

*Adv Ther.* 2008 Sep;25(9):894-913. doi: 10.1007/s12325-008-0093-z.

## **LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome.**

Blum K<sup>1</sup>, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T.

### **Author information**

### **Abstract**

**INTRODUCTION:** This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen, Inc., La Jolla, CA, USA).

**METHODS:** A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed.

**RESULTS:** Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all  $P < 0.01$ ), increased perception of overeating, enhanced quality of sleep, increased happiness (all  $P < 0.05$ ), and increased energy ( $P < 0.001$ ). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-gamma2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment ( $r = 0.42$ ,  $P = 0.045$ ).

**CONCLUSION:** If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.

PMID: 18781289 DOI: [10.1007/s12325-008-0093-z](https://doi.org/10.1007/s12325-008-0093-z)

[Indexed for MEDLINE]



---

**Publication type, MeSH terms, Substances**

---

**LinkOut - more resources**